Maze Therapeutics (NASDAQ:MAZE) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Maze Therapeutics (NASDAQ:MAZE) from a sell rating to a hold rating in a report published on Saturday morning.

A number of other research firms also recently weighed in on MAZE. JPMorgan Chase & Co. lifted their target price on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st. HC Wainwright lifted their target price on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Truist Financial dropped their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Finally, Guggenheim lifted their target price on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Trading Down 3.3%

Shares of Maze Therapeutics stock opened at $25.56 on Friday. The business has a fifty day simple moving average of $33.41 and a two-hundred day simple moving average of $37.92. Maze Therapeutics has a 1 year low of $8.81 and a 1 year high of $53.65. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -10.10 and a beta of 2.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 15.50.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. Research analysts forecast that Maze Therapeutics will post -2.63 EPS for the current year.

Insider Transactions at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 2,500 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total transaction of $73,600.00. Following the sale, the senior vice president directly owned 12,965 shares in the company, valued at approximately $381,689.60. The trade was a 16.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $29.46, for a total value of $441,900.00. Following the sale, the chief marketing officer owned 15,000 shares in the company, valued at approximately $441,900. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 70,000 shares of company stock worth $2,955,775. Insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in shares of Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after purchasing an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after purchasing an additional 362,060 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after purchasing an additional 94,529 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Maze Therapeutics by 9.0% during the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock worth $35,111,000 after purchasing an additional 69,771 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its stake in shares of Maze Therapeutics by 40.8% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company’s stock worth $31,793,000 after acquiring an additional 222,251 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.